Then, we identified 6 possible targets (SLC6A4, MIF, DPP4, PRF1, SERPING1, and IL6) of emetine against LUAD/COVID-19 by a network pharmacology approach, and the results of functional enrichment analysis of these 6 genes suggested that anti-LUAD/COVID-19 effects of emetine were mediated by antiviral and immunomodulation. Here, PRF1 is linked to COVID-19.